| Reisa A. Sperling | |
|---|---|
| Photo placeholder | |
| Affiliations | Brigham and Women's Hospital Harvard Medical School |
| Country | USA |
| H-index | 200 |
| ORCID | 0000-0001-5571-3614 |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Biomarkers, Amyloid, Prevention |
Reisa A. Sperling is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Reisa A. Sperling is a leading researcher in the field of neurodegenerative diseases, affiliated with Brigham and Women's Hospital and Harvard Medical School. Their research focuses on Biomarkers, Amyloid, Prevention, with particular emphasis on Alzheimer's Disease. With an h-index of 200, Sperling is among the most cited researchers in the neuroscience field.
Sperling's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease. Her pioneering research has shaped the field of preclinical Alzheimer's disease and preventive therapeutics.
Dr. Reisa Sperling's research centers on the early detection and prevention of Alzheimer's disease. Her work has been instrumental in advancing our understanding of preclinical Alzheimer's disease - the phase before clinical symptoms appear when intervention may be most effective.
Tau Positron Emission Tomography (PET) Imaging: Dr. Sperling has pioneered the use of tau PET imaging to visualize tau pathology in the living brain, enabling earlier diagnosis and tracking of disease progression.
Amyloid Pathology: Her studies have significantly advanced our understanding of how amyloid plaques develop and contribute to cognitive decline in older adults.
Prevention Trials: As an active member of the A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer's), Dr. Sperling has led efforts to develop preventive treatments for individuals at risk for Alzheimer's disease.
Plasma Biomarkers: Her research includes investigation of novel plasma biomarkers, particularly pTau217, for early detection of Alzheimer's pathology.
Neuroimaging Biomarkers: Dr. Sperling's work has established key neuroimaging markers for detecting early changes in the Alzheimer's disease continuum.
Dr. Sperling has made substantial contributions to multiple landmark studies:
Harvard Aging Brain Study: Contributing investigator to this foundational study examining preclinical Alzheimer's disease biomarkers.
Alzheimer's Disease Neuroimaging Initiative (ADNI): Active participant in this international research effort to define the progression of Alzheimer's disease.
PREVENT-AD Research Group: Member of this consortium focused on preventing Alzheimer's disease in at-risk individuals.
A4 Study: Leadership role in this landmark prevention trial testing anti-amyloid treatment in cognitively normal older adults with elevated amyloid.
LEADS Consortium: Contributor to the Longitudinal Early-Onset Alzheimer's Disease Study.
Dr. Sperling's research has transformed clinical practice by:
Dr. Sperling has authored over 500 publications, including landmark papers on:
Dr. Sperling's contributions have been recognized through numerous awards and leadership positions in the Alzheimer's research community. She serves on advisory boards for major Alzheimer's disease research organizations and has been instrumental in shaping national and international research priorities.
Dr. Sperling has mentored numerous clinicians and researchers in the field of Alzheimer's disease, training the next generation of dementia specialists. She has supervised graduate students, postdoctoral fellows, and clinical fellows who have gone on to lead academic research programs.
Ongoing and planned research directions include:
Dr. Sperling leads and participates in major research consortia:
The study of Reisa A. Sperling has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.